Endometrial carcinoma. Malignant neoplasm of endometrium
Conditions
Interventions
Intervention 1: Intervention group: In this study, we intend to refer patients with endometrial cancer who have been referred to Mahdieh / Imam Hossein (AS) Hospital, and are on the list of gynecologi
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: All women with endometrial carcinoma pathology, regardless of age and histological stage, who have referred to Mahdieh / Imam Hossein (AS) Medical Center between 1401-1402 and are on the list of staging surgery of this center.
Exclusion criteria
Exclusion criteria: Pregnancy Diabetes or the use of metformin or other blood sugar control drugs Liver or kidney dysfunction Simultaneous cancers over the last 5 years Use of chemotherapy drugs or hormone therapy during the last 3 months Any allergy to Biguanides or contraindications to the use of this class of drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the expression of ki-67 gene in tissue samples of endometrial cancer after using metformin. Timepoint: Before treatment and on the day of surgery. Method of measurement: Ki-67 tissue staining (IHC).;Changes in p-53 gene expression in endometrial cancer tissue samples after metformin use. Timepoint: Before treatment and on the day of surgery. Method of measurement: P-53 tissue staining (IHC).;Determining the effect of metformin on tumor size reduction. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measurement of mass during diagnosis by ultrasound and by the surgeon.;Determining the effect of metformin use in reducing body mass index. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measuring Body Mass Index (weight over height^2). | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in p-53 gene expression in endometrial cancer tissue samples after metformin use. Timepoint: Before treatment and on the day of surgery. Method of measurement: P-53 tissue staining (IHC).;Determining the effect of metformin on tumor size reduction. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measurement of mass during diagnosis by ultrasound and by the surgeon.;Determining the effect of metformin use in reducing body mass index. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measuring Body Mass Index (weight over height^2). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMinoo Rostami
Shahid Beheshti University of Medical Sciences
Outcome results
None listed